Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience
Matteo Passerini(University of Milan), Giuliano Rizzardini, Matteo Bolis(Ospedale Amedeo di Savoia), Simona Landonio(ASST Fatebenefratelli Sacco), V Scalzi(ASST Fatebenefratelli Sacco), G. Gubertini, Elena Ricci(Mario Negri Institute for Pharmacological Research), Simone Passerini(Office of Infectious Diseases), Monica Schiavini(ASST Fatebenefratelli Sacco), C. Magni(ASST Fatebenefratelli Sacco), Alessandro Luciano Croci(Office of Infectious Diseases), Fosca Niero(Luigi Sacco Hospital), Massimo Galli(Luigi Sacco Hospital)
Cited by 24
Related Papers
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
|Cell|2021|656
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
|New England Journal of Medicine|2022|264
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|115
HIV and Metabolic Syndrome
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2007|110